Fujirebio Confirms Its Engagement in Blood-based Alzheimer’s Disease Biomarker Testing with the Launch of the Fully Automated Lumipulse® G ?-Amyloid 1-42 and ?-Amyloid 1-40 Plasma Assays for Research Use Only
GENT, Belgium & MALVERN, Pa. & TOKYO--(BUSINESS WIRE)--#FNCoE--H.U. Group Holdings Inc. and its wholly-owned subsidiary…